This page shows the latest amyloidosis news and features for those working in and with pharma, biotech and healthcare.
The first award of the evening recognised Excellence in Patient Education and Support and went to One Step Further – Resetting Expectations in hATTR Amyloidosis by Alnylam, with support from akt health.
Around 350 million people worldwide are living with rare disorders, approximately 80% of which are genetic in origin, including AA amyloidosis, Adrenoleukodystrophy and Ehlers-Danlos syndrome.
ATTR amyloidosis is an underdiagnosed and rapidly progressive disease caused by misfolded transthyretin proteins, which accumulate as amyloid deposits in various parts of the body, including the heart, resulting in cardiomyopathy ... October. Patisiran
The protein, which is called transthyretin (TTR), can become abnormal in ATTR amyloidosis and break apart into smaller pieces (amyloid). ... for standard of care Onpattro (patisiran), Alnylam’s earlier RNAi ATTRv amyloidosis therapy that is
The liver-targeted antisense therapy is in phase 3 trials for the treatment of transthyretin amyloidosis, a systemic, progressive and fatal condition. ... Eplontersen has the potential to halt the progression of TTR-mediated amyloidosis irrespective of
In addition to $13bn in sales from Comirnaty, anticoagulant Eliquis (apixaban) grew by 19% to $1.3bn, amyloidosis therapy Vyndaqel/Vyndamax (tafamidis) was up by 42% to $502m and Inlyta increased
More from news
Approximately 4 fully matching, plus 43 partially matching documents found.
Remote monitoring in practice. A prominent example of effective remote monitoring can be found in trials for ATTR cardiac amyloidosis (ATTR-CM).
Onpattro was approved to treat adults with the. destruction of nerves that results from a rare disease, hereditary transthyretin- mediated (hATTR) amyloidosis, and was launched with a $450, 000 per year ... pipeline. The company submitted its lumasiran
The drug is licensed to treat to adults with stage 1 or 2 polyneuropathy, the destruction of nerves that results from hereditary transthyretin- mediated (hATTR) amyloidosis, a rare, rapidly progressive, fatal ... The company is working with patient
spondylitis. For instance, the Portuguese Association of Amyloidosis (APP) is petitioning parliament for access to Pfyzer's Vyndaqel (tafamidis). ... The drug is to be granted marketing approval by the European Medicines Agency for the treatment of
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
What is Light-chain (AL) Amyloidosis? Amyloidosis is a group of rare, serious conditions caused by the abnormal folding of amyloid proteins that build up in tissue throughout the body. ... enhance recognition of AL Amyloidosis itself and the therapies
Three monoclonal antibodies were presented on the last day of ASCO - two in multiple myeloma and one in amyloidosis.
What does the future hold for Light-chain Amyloidosis?.
More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.
No results were found
We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...